Organic Process Research & Development · 2008 · 27 citations · 8 references
PharmacyMedicinal ChemistryPharmacologyAntimicrobial PharmacologyDrug DiscoveryMycologyAntifungal AgentsAntifungal PharmacologyAntifungal PharmacotherapyAntifungal TherapyFungal BiochemistryFungal Secondary MetabolitesAntifungal TreatmentsCandida TherapyCrystallizationInvasive Candidiasis TreatmentNew Antifungal AgentsNovel Antifungal Drug DevelopmentPhysical PropertiesSingle-crystal X-ray Diffraction
Many years ago anidulafungin 1 was identified as a potentially useful medicine for the treatment of fungal infections. Its chemical and physical properties as a relatively high molecular weight semisynthetic derived from echinocandin B proved to be a significant hurdle to its final presentation as a useful medicine. It has recently been approved as an intravenous treatment for invasive candidaisis, an increasingly common health hazard that is potentially life-threatening. The development and commercialization of this API, which is presented as a molecular mixture of anidulafungin and d -fructose is described. This includes, single crystal X-ray structures of the starting materials, the echinocandin B cyclic-peptide nucleus (ECBN·HCl) and the active ester 1-({[4′′-(pentyloxy)-1,1′:4′,1′′-terphenyl-4-yl]carbonyl}oxy)-1 H -1,2,3-benzotriazole (TOBt). Details of the structure and properties of starting materials, scale-up chemistry and unusual crystallization phenomena associated with the API formation are discussed.
8
F. Benz, F. Knüsel, J. Nüesch et al. · Helvetica Chimica Acta · 1974 · 249 citations
Manuel Debono, William W. Turner, Lisa LaGrandeur et al. · Journal of Medicinal Chemistry · 1995 · 113 citations
Deacylation of echinocandin B by Actinoplanes utahensis.
LA VERNE D. BOECK, D. S. Fukuda, Bernard J. Abbott et al. · The Journal of Antibiotics · 1989 · 88 citations
James M. Balkovec, Regina M. Black, Milton L. Hammond et al. · Journal of Medicinal Chemistry · 1992 · 71 citations